BioSpace News Archive

On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China.

Kraig Biocraft Laboratories, Inc., announces that it has expanded its production of spider silk with the creation of the next generation of BAM-1 hybrid.

Freyja Healthcare, an early-stage medical device company specializing in women’s health, has secured $8 million in new funding.

Carisma Therapeutics Inc. today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on Tuesday, July 9th at 9:10 am ET.

Zevra Therapeutics, Inc. today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer.

Soligenix, Inc. announced today positive clinical results from a comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine gel) in the treatment of cutaneous T-cell lymphoma (CTCL).

Shanghai Junshi Biosciences Co., Ltd announced that the National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for toripalimab (product code: JS001).

QurAlis Corporation today announced it is expanding its industry-leading precision medicine antisense oligonucleotide (ASO) splicing expertise beyond neurodegeneration into Fragile X syndrome (FXS).

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the presentation of positive preclinical progress of its development of a potential treatment for type 1 diabetes at two scientific meetings.

BioVie Inc. today announced data from two presentations at the Advanced Therapeutics in Movement and Related Disorders Congress® (ATMRD Congress) held June 21-25, 2024 in Washington, D.C.